- Ledipasvir (GS-5885)
Synonyms: GS 5885;GS5885;GS-5885;Ledipasvir;GS-5885/Ledipasvir;
gs-5885/gs5885;Ledipasvir / GS 5885;GS 588
Molecular Weight: 889.0
Product Categories: API
Categories: NS5A inhibitors;Fluorenes;Carbamates;Benzimidazoles;Cyclopropanes;
Purity : 98%
Storage at -20°C
Appearance : White powders
Package : 50g/foil bag
Usage : Ledipasvir is most commonly used in combination with sofosbuvir for treatment in chronic hepatitis C genotype 1 patients. This drug has been tested and shown efficacy in treatment-naive and treatment experienced patients.
Ledipasvir — Description :
Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S.
approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. The ledipasvir/sofosbuvir
combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat
patients with genotypes 1a or 1b without PEG-interferon or ribavirin.SARMS Raw Powder Ledipasvir (GS-5885) CAS:
1256388-51-8 Treating hepatitis C
Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein.
Data presented at the 20th Conference on Retroviruses and Opportunistic Infections
in March 2013 showed that a triple regimen of the nucleotide analog inhibitor
sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both
treatment-naive patients and prior non-responders with HCV genotype 1.The sofosbuvir/ledipasvir coformulation is being
tested with and without ribavirin. In February 2014 Gilead has filed for United States
Food and Drug Administration (FDA) approval of ledipasvir/sofosbuvir oral treatment,
without interferon and ribavirin.SARMS Raw Powder Ledipasvir (GS-5885) CAS: 1256388-51-8 Treating hepatitis C
GS-5885 is an inhibitor of the hepatitis C virus (HCV) NS5A protein and exhibits potent
suppression of genotype 1 HCV replicons. GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA
ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype
1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV
genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. SARMS Raw Powder Ledipasvir (GS-5885) CAS: 1256388-51-8 Treating hepatitis C.Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Ledipasvir (formerly GS-5885) is currently in Phase III clinical trials.